PURMX Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PURMX Therapeutics, Inc. - overview
Established
2021
Location
Hiroshima-shi, Hiroshima, Japan
Primary Industry
Biotechnology
About
Founded in 2021 and based in Hiroshima, Japan, PURMX Therapeutics, Inc. operates as a research and development company that develops nucleic acid drugs containing microRNA as an active ingredient. The company develops treatments for malignant thoracic tumors. In May 2022, PURMX Therapeutics, Inc.
raised JPY 850 million in Series A funding from new investors Hiroshima Venture Capital, Mitsubishi UFJ Capital, Osaka University Venture Capital, QB Capital, and University of Tokyo Edge Capital Partners. The company operates as a drug developer, which focuses on replacing lacking small RNAs (microRNA) in cells. The company now has one pipeline undergoing, MIRX002, a nucleic acid medicine for malignant pleural mesothelioma.
Current Investors
University of Tokyo Edge Capital Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.purmx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.